Side-by-side · Research reference
GDF-8vsPancragen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED23/48 cited
BAnimal-StrongHUMAN-REVIEWED23/39 cited
GDF-8
TGF-β Superfamily · Negative Muscle Regulator
15–20%Muscle mass gain (MSTN−/−)
Not administered — research target for inhibition
01Mechanism of Action
Parameter
GDF-8
Pancragen
Primary target
Activin type II receptors (ActRIIA/B) on skeletal muscleIglesias 2026
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Pathway
MSTN → ActRII/TGFBR1 → Smad2/3 signaling → muscle protein synthesis suppression
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Downstream effect
Restricts muscle hypertrophy, limits satellite cell activation, increases proteolysis via ubiquitin-proteasome and autophagy pathwaysGong 2026Iglesias 2026
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Feedback intact?
Yes — part of muscle-pituitary endocrine axis; muscle-derived MSTN influences FSH synthesisIglesias 2026
Yes — preserves physiological glucose-insulin response
Origin
Endogenous myokine secreted by skeletal muscle; circulates systemically as latent complexIglesias 2026
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Antibody development
—
—
02Dosage Protocols
Parameter
GDF-8
Pancragen
Clinical use
None — MSTN is a research target for inhibition, not a therapeutic peptide administered to humans
Sold by research suppliers (e.g., CertaPeptides) for in vitro / animal studies only.
—
Inhibition strategies
Monoclonal antibodies, VLP-based active immunotherapy, gene editing (CRISPR)
—
VLP immunogen (MS2.87-97)
Active immunization protocol in mice — elicits anti-MSTN antibodies without GDF11 cross-reactivityJacquez 2026
Reduces body fat, increases muscle mass and grip strength; no major safety concerns in animal models.Jacquez 2026
—
Dual immunization (MSTN + Activin A)
Combined active immunization in GH-deficient miceMansoor 2026
Improves skeletal muscle performance beyond single-target inhibition.Mansoor 2026
—
Gene editing outcomes
Precision CRISPR edits produce double-muscle phenotype, improved carcass quality in livestock
Pleiotropic effects on metabolism, reproduction, and welfare require systematic evaluation.
—
Primate dose (rhesus macaque)
—
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
Effective concentration (in vitro)
—
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
Diabetes model
—
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
03Metabolic / Fat Loss Evidence
Parameter
GDF-8
Pancragen
Primary mechanism
MSTN loss-of-function reduces fat accumulation independent of muscle mass effects
—
Human genetic evidence
Humans with MSTN function-disrupting variants have increased muscle mass, strength, and reduced adiposityHerman 2026
—
Animal model outcomes
VLP-immunized mice: reduced age-associated weight gain, significantly lower body fat by DEXAJacquez 2026
—
Adipose-muscle crosstalk
MSTN modulates myostatin-TAZ signaling; inhibition shifts adipose expansion toward hyperplasiaLi 2026
—
Age-related effects
MSTN upregulation linked to age-dependent muscle atrophy and fat accumulation
—
04Side Effects & Safety
Parameter
GDF-8
Pancragen
Genetic null phenotype
No known adverse phenotypes in humans or mice with MSTN loss-of-functionJacquez 2026
—
Antibody cross-reactivity risk
Non-selective inhibitors may block GDF11, affecting cardiac and neural function
—
VLP immunotherapy safety
No major safety concerns in mice; rare hypersensitivity possibleJacquez 2026
—
Pleiotropic effects (gene editing)
MSTN editing may affect reproductive performance, metabolic homeostasis, and animal welfare
—
Assay variability
Circulating MSTN levels often fail to mirror intramuscular changes; clinical interpretation challengingIglesias 2026
—
Reported adverse events
—
None documented in primate studies
Human safety data
—
No published human trials; clinical use limited to Russian gerontology protocols
Absolute Contraindications
GDF-8
- ·Not applicable — MSTN is not administered as a therapeutic agent
Pancragen
—Relative Contraindications
GDF-8
- ·Inhibition strategies contraindicated in conditions requiring maintained muscle proteostasis (theoretical)
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
05Administration Protocol
Parameter
GDF-8
Pancragen
1. Research context only
GDF-8 (myostatin) is not administered to humans. It is studied as a target for inhibition using monoclonal antibodies, active immunotherapy (VLP-based vaccines), or gene editing (CRISPR). Research-grade peptide supplied by vendors like CertaPeptides is intended for in vitro and animal studies only.
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
2. Inhibition strategies
Clinical development focuses on blocking MSTN activity via: (1) neutralizing monoclonal antibodies targeting mature MSTN or ActRII receptors; (2) active immunotherapy generating endogenous anti-MSTN antibodies (e.g., MS2.87-97 VLP platform); (3) precision gene editing to disrupt MSTN expression in livestock or therapeutic contexts.
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
3. VLP immunization protocol (animal model)
MS2.87-97 VLP administered to mice elicits anti-MSTN antibodies targeting a discrete epitope in mature MSTN protein. Immunization schedule and dose optimized for sustained antibody response without GDF11 cross-reactivity. No human protocols established.Jacquez 2026
No specific timing constraints documented. Administered once daily in primate protocols.
4. Gene editing considerations
CRISPR-mediated MSTN knockout produces double-muscle phenotype in livestock (cattle, swine, sheep). Ethical frameworks and welfare assessments required; pleiotropic effects on reproduction, metabolism, and health must be systematically evaluated before human translation.
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014